Request Consultation
Very firstly, biologics are defined as the complex, expensive pharmaceutical products developed from living organisms, such as animal cells, yeast, or bacteria. Whereas biosimilars are highly similar, FDA-authorized entities of these original biologics that facilitate the same safety & efficacy, at an affordable price.
Moreover, the advanced biologics are widely employed in treating complex or chronic diseases, especially cancer, diabetes, autoimmune disorders, & arthritis. On the other hand, biosimilars are created to mimic an already-approved biologic to enhance treatment access & decrease healthcare expenditures.
Biosimilars Market v/s Biologics Market Insights
According to Towards Healthcare Insights, the global biosimilar market size is estimated to grow from USD 40.87 billion in 2025 at 17.6% CAGR (2026 to 2035) to reach an estimated USD 206.75 billion by 2035. While the biologics market size is projected to reach USD 1009.33 billion by 2035, growing from USD 522.06 billion in 2026, at a CAGR of 7.6% during the forecast period from 2026 to 2035.
This is because biologics continue to dominate advanced therapies for chronic diseases, cancer, autoimmune disorders, and rare conditions, supported by strong innovation pipelines and rising healthcare investments globally. Simultaneously, biosimilars are expanding rapidly due to patent expirations of major biologic drugs, increasing demand for affordable treatment alternatives, supportive regulatory frameworks, and broader adoption across emerging and developed healthcare markets worldwide.
Various significant drivers are impacting the global development & growth of the numerous biologics and biosimilars, such as
- The globe is experiencing expiration of patents & timelines for substantial originator biologics, along with many manufacturers producing and unveiling novel, highly similar, inexpensive biosimilar options to acquire market share.
- Most notable catalyst is a massive rise in burden of cancer, rheumatoid arthritis, and diabetes incidences, which necessitates long-term, biologic-based treatments.
Besides this, the global demand for biosimilars is mainly propelled by rising budget strain on healthcare systems & patients, while these biosimilars are majorly reducing treatment spending, and enable healthcare payers to control expenditures & expansion of patient access. - Alongside, continuous groundbreakings in monoclonal antibodies, gene therapies, and latest platforms, coupled with heavy R&D investments from giant pharma companies into biologics, support the overall progression.
- Subsidiary driver is the emerging government incentives, such as the Production Linked Incentive (PLI) scheme in countries, including India, which are fostering local production, with minimal spending & encouraging the export of biological APIs.
Recent Highlights of Biologics & Biosimilars in 2026
- In May 2026, Amgen invested a further US$300.00 million in its U.S. manufacturing network, to reinforce its large biologics facility in Juncos, Puerto Rico, to empower next-generation production capacity, workforce progression & supply reliability.
- In April 2026, Aurigene Pharmaceutical Services raised a $100 million investment strategy to bolster progression in its CRDMO services across small molecules, peptides, nutraceuticals & biologics.
- In March 2026, Sandoz, the global player in cost-effective medicines, announced the establishment of a novel biosimilar development, manufacturing & supply unit.
- In February 2026, the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) recommended the approval of a marketing authorization for three biosimilar medicines, i.e. Bysumlog (insulin lispro), Dazparda (insulin aspart), & Fubelv (etanercept).
Biologics and Biosimilars: Shaping the Next Era of Healthcare
Together, biologics and biosimilars are reshaping modern healthcare by balancing innovation with affordability. While biologics continue advancing precision treatments for complex diseases, biosimilars are widening patient access through lower costs and stronger market competition. Growing investments, supportive regulations, expanding manufacturing capabilities, and increasing chronic disease prevalence will continue accelerating both markets worldwide. Consequently, the next decade is expected to witness transformative opportunities for pharmaceutical companies, healthcare providers, and patients alike.
About the Experts
Aditi Shivarkar
Aditi leads as Vice President at Towards Healthcare and brings over 15 years of experience in healthcare research, innovation, and strategy. She works closely with data from across the healthcare sector and turns it into clear direction that companies can actually use. Her work covers pharmaceuticals, medical devices, and digital health. She helps businesses understand where the market is going and how to respond with confidence. Aditi focuses on practical thinking, strong decision-making, and delivering real results that make a difference.
Aman Singh
Aman Singh brings over 13 years of experience in healthcare research and consulting. He studies global healthcare trends and keeps a close eye on areas like biotech, AI in healthcare, and new treatment approaches. At Towards Healthcare, he leads the research team and makes sure the work stays accurate, useful, and easy to understand. Aman breaks down complex changes in the industry and helps businesses make smart, informed decisions.
Piyush Pawar
Piyush Pawar works as Senior Manager for Sales and Business Growth at Towards Healthcare, with more than 10 years of experience in the healthcare space. He works directly with clients and helps them find the right research for their needs. He makes sure clients understand the insights and know how to use them in their business. Piyush builds strong relationships and focuses on helping companies grow by turning research into clear, practical action.
